Surgeons warn it is too early to recommend a TAVR-first strategy for low-risk patients

[ad_1] One key takeaway from the STS/EACTS statement is that, using the same inclusion criteria found in the PARTNER 3 and Evolut Low Risk trials, SAVR is already associated with…

TAVR or SAVR? Where things stand now, from a surgeon’s perspective

[ad_1] While the 5-year results of the PARTNER 3 Low-Risk trial and the 4-year results from the Evolut Low-Risk trial both showed excellent results for TAVR, Grubb said the real…

TAVR triumphs over surgery: Exploring 4-year data from the Evolut Low Risk trial

[ad_1] Steven Yakubov, MD, director of the MidWest Cardiology Research Foundation at OhioHealth Riverside Methodist Hospital, looked at overall valve performance for this study. This included structural valve deterioration, non-structural…

New polymeric heart valve, designed to grow with pediatric patients, implanted for first time

[ad_1] The first-in-human implant involved a 21-month-old patient who had previously received a homograft that became severely stenotic and had to be removed. Early follow-up evaluations confirmed that the patient…